Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging
Soluble interleukin-2 receptor serum level is a useful marker of hidradenitis suppurativa clinical staging
复制标题
DOI：
10.1080/13547500903075218
复制
发表时间：
2009-01-01
期刊：
影响因子：
2.6
通讯作者：
Szepietowski, Jacek C.
中科院分区：
文献类型：
--
作者：
Matusiak, Lukasz;Bieniek, Andrzej;Szepietowski, Jacek C.
化脓性汗腺炎（HS）是一种复发性、使人衰弱的化脓性皮肤病。最大的挑战是选择最佳的治疗方法。治疗有效性的评估目前与基于Hurley或Sartorius分级系统的疾病活动的临床观察相关。HS患者的详细检查和疾病严重程度的评估通常是耗时的，无疑是主观的。关于这些因素，需要实验室的研究结果，这将有助于解决问题。本研究的目的是确定可溶性白细胞介素2受体（sIL-2 R）血清浓度作为HS临床分期的标志物的有效性，并与常用的实验室测量，包括白色血细胞计数，C-反应蛋白和红细胞沉降率进行比较分析。对54例HS患者进行的所有这些实验室参数的统计学分析显示，血清sIL-2 R水平似乎是评估疾病阶段的最敏感指标。此外，血清sIL-2 R浓度与Hurley's HS分级之间存在较强的相关性。结论：血清sIL-2 R水平可作为HS患者疾病分期的一个有价值的指标。
Hidradenitis suppurativa (HS) is a recurrent, debilitating suppurative skin disease. The major challenge is the choice of optimal treatment. Assessment of treatment effectiveness is currently associated with clinical observations of disease activity based on Hurley's or Sartorius' grading system. Detailed examination of patients with HS and evaluation of disease severity is frequently time-consuming and undoubtedly subjective. With regard to these factors, there is a need for laboratory findings that will help resolve the problem. The aim of this study was to determine the usefulness of soluble interleukin-2 receptor (sIL-2R) serum concentration as a marker of HS clinical staging and comparative analysis with the commonly conducted laboratory measurements, including white blood cell count, C-reactive protein and erythrocyte sedimentation rate. The statistical analysis of all these laboratory parameters conducted within a group of 54 individuals with HS revealed that sIL-2R serum level seems to be the most sensitive measurement for evaluation of disease stage. Moreover, the existence of strong dependences between sIL-2R serum concentration and Hurley's HS grading system were demonstrated. In conclusion, we believe that sIL-2R serum level could be used as a valuable marker for disease staging in patients with HS.